These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2603597)

  • 21. [A clinical-pharmacological case (1). Action of cisapride (Prepulsid) on bladder function].
    Meier C; Hess C; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1996 Jan; 85(3):62-4. PubMed ID: 8578051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in lower urinary tract function in children with hyperactive urinary bladder treated with combined therapy].
    Danilova TI; Medvedeva EV; Vasil'eva ZhB; Danilov VV
    Urologiia; 2007; (3):77-81. PubMed ID: 17722623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisapride to relieve dysphagia.
    Sharman JM
    Br J Gen Pract; 1993 Dec; 43(377):534. PubMed ID: 8312027
    [No Abstract]   [Full Text] [Related]  

  • 25. Cisapride and the lazy lower oesophageal sphincter.
    Dent J
    J Gastroenterol Hepatol; 1989; 4(5):490-1. PubMed ID: 2491215
    [No Abstract]   [Full Text] [Related]  

  • 26. Cisapride and 5-hydroxytryptamine enhance motility in the canine antrum via separate pathways, not involving 5-hydroxytryptamine1,2,3,4 receptors.
    de Ridder WJ; Schuurkes JA
    J Pharmacol Exp Ther; 1993 Jan; 264(1):79-88. PubMed ID: 8093733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisapride, a drug for long-term treatment?
    Harvengt C
    Acta Gastroenterol Belg; 1990; 53(4):369-71. PubMed ID: 2096582
    [No Abstract]   [Full Text] [Related]  

  • 28. Rationale for the development of a novel gastrointestinal prokinetic, cisapride.
    Reyntjens A
    Scand J Gastroenterol Suppl; 1989; 165():1-6; discussion 27-8. PubMed ID: 2690319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormalities in the contractile properties of colonic smooth muscle in idiopathic slow transit constipation.
    Slater BJ; Varma JS; Gillespie JI
    Br J Surg; 1997 Feb; 84(2):181-4. PubMed ID: 9052428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Novara G
    Eur Urol; 2008 Mar; 53(3):618-9. PubMed ID: 17804151
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical effect of new alpha-adrenergic blocker on micturition disturbance of neurogenic bladder and lower urinary tract obstruction].
    Takimoto Y; Kitamura K; Fuse T; Kawazoe K; Hirano D; Amagai T; Kiyotaki S
    Hinyokika Kiyo; 1983 Feb; 29(2):255-63. PubMed ID: 6145342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Studies of urodynamics. VIII. Clinical and experimental studies of effects of prostaglandin E2 and prostaglandin F2 alpha on lower urinary tract (author's transl)].
    Kaneko S; Kato Y; Tsujihashi H; Boku E; Kunikata S; Kataoka K; Nagai N; Matsuura T; Yachiku S; Kurita T
    Nihon Hinyokika Gakkai Zasshi; 1981 Oct; 72(10):1221-6. PubMed ID: 6948976
    [No Abstract]   [Full Text] [Related]  

  • 33. [Prokinetic drugs in digestive disorders].
    Carella G; Marra L
    Clin Ter; 1993 Sep; 143(3):219-24. PubMed ID: 8222553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of various prokinetic drugs on gastrointestinal transit times in patients with progressive systemic scleroderma].
    Folwaczny C; Läritz M; Meurer M; Endres SP; König A; Schindlbeck N
    Z Gastroenterol; 1997 Oct; 35(10):905-12. PubMed ID: 9432812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence. A multicenter study for optimizing dosage].
    Mazur D; Göcking K; Wehnert J; Schubert G; Herfurth G; Alken RG
    Urologe A; 1994 Sep; 33(5):447-52. PubMed ID: 7974935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of alpha-1 adrenergic innervation of the urinary bladder in human neurogenic vesical dysfunction.
    Vaidyanathan S; Rao MS; Sharma PL; Sachdeva NK
    Indian J Med Res; 1983 Apr; 77():529-33. PubMed ID: 6135662
    [No Abstract]   [Full Text] [Related]  

  • 37. [Prokinetic activity and antral inflammation. Usefulness of cisapride combined with H2 antagonists in gastritis].
    Dallera F; Scanzi G; Gendarini A
    Clin Ter; 1994 Jan; 144(1):23-6. PubMed ID: 8168347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cisapride marketed for use in gastroesophageal reflux disease.
    Clin Pharm; 1993 Dec; 12(12):876, 879. PubMed ID: 8137603
    [No Abstract]   [Full Text] [Related]  

  • 39. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.
    McKenna CJ; Mills JG; Goodwin C; Wood JR
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):817-22. PubMed ID: 8574711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.